TPICO
www.themegallery.com
3
                4
    Non-Invasive 5
GDP      ⅛  6
EMRO–       –   –       7
8
9
10
11
12
Branding      Marketing          R&D 13
R&D       Innovative vs. Imitative Developments                                   Global R&D Spend Analysis               ...
15
16
17
Plasma Fractionation                 Vaccines      Bio/Nano/Onco/MAB 18
19
20
21
22
–    –    –––        23
24
TPICO             -                 -                     -        25
دارو و نظام   سلامتDr zargari
Upcoming SlideShare
Loading in …5
×

دارو و نظام سلامتDr zargari

337 views

Published on

فرهاد زرگری ,

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
337
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
6
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

دارو و نظام سلامتDr zargari

  1. 1. TPICO
  2. 2. www.themegallery.com
  3. 3. 3
  4. 4.     4
  5. 5.  Non-Invasive 5
  6. 6. GDP ⅛ 6
  7. 7. EMRO– – – 7
  8. 8. 8
  9. 9. 9
  10. 10. 10
  11. 11. 11
  12. 12. 12
  13. 13. Branding  Marketing  R&D 13
  14. 14. R&D Innovative vs. Imitative Developments Global R&D Spend Analysis 2002 2004 2006 2008 2009 2010 2012 2014 2016Pharma R&D Spend ($bn) 68.4 86.2 104.9 125.6 124.5 127.4 132.3 139.1 145.5 Growth per year 11% 11% 8% -1% 2% 2% 3% 2% WW Prescription (Rx) 350 448 530 628 644 662 699 746 785 Sales ($bn) Growth per year 11% 9% 8% 3% 3% 2% 3% 2%R&D as % of WW Rx sales 19.6% 19.3% 19.8% 20.0% 19.3% 19.2% 18.9% 18.6% 18.5% Cumulative R&D spend $798bn (02-09) Annual R&D spend 10.6% growth (02-08) Annual R&D spend 2.3% growth (09-16) 14
  15. 15. 15
  16. 16. 16
  17. 17. 17
  18. 18. Plasma Fractionation  Vaccines  Bio/Nano/Onco/MAB 18
  19. 19. 19
  20. 20. 20
  21. 21. 21
  22. 22. 22
  23. 23. – – ––– 23
  24. 24. 24
  25. 25. TPICO - - - 25

×